{"entity":{"id":"bicycle-therapeutics","kind":"company","name":"Bicycle Therapeutics","aka":[],"tldr":"Inventor of bicyclic peptide drug conjugates; its lead Nectin-4 conjugate was deprioritised in 2026 after regulatory feedback.","summary":"Bicycle Therapeutics, based in Cambridge in the United Kingdom and listed as BCYC, is the inventor of bicyclic peptide drug conjugates, a class of small, synthetic alternatives to antibody-drug conjugates. Its lead Nectin-4 conjugate, zelenectide pevedotin, or BT8009, was deprioritised in 2026 after regulatory feedback, BT5528 targets EphA2, and its Bicycle radio-conjugates are partnered with Bayer and Novartis in radiopharmaceuticals. OnCo links it to bladder and urothelial cancer, to the zelenectide pevedotin drug record, and to the peptide-drug and small-molecule-drug conjugate technology. Whether bicyclic peptides find their place as radiopharmaceutical carriers rather than as cytotoxic conjugates is the question the 2026 decision poses. Zelenectide pevedotin has its own page.","asOf":"2026-09-07","links":[{"label":"Official website","url":"https://www.bicycletherapeutics.com"}],"tags":[],"related":[],"cancers":[],"sections":["adcs"],"technologies":["peptide-drug-conjugate"],"targets":[],"drugs":["zelenectide-pevedotin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07450859","nct05163041","nct04561362","nct06225596","nct06840483","nct04180371","nct06933329"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Cambridge","country":"GB","companyType":"biotech","website":"https://www.bicycletherapeutics.com","ticker":"BCYC","investors":["sv-health-investors","novartis-venture-fund"],"funding":[]},"route":"/companies/bicycle-therapeutics/","neighbours":{"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"}],"technology":[{"id":"peptide-drug-conjugate","kind":"technology","name":"Peptide-drug & small-molecule-drug conjugates","route":"/technologies/peptide-drug-conjugate/"}],"drug":[{"id":"zelenectide-pevedotin","kind":"drug","name":"Zelenectide pevedotin","route":"/drugs/zelenectide-pevedotin/"}],"trial":[{"id":"nct07450859","kind":"trial","name":"A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","route":"/trials/nct07450859/"},{"id":"nct04180371","kind":"trial","name":"Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression","route":"/trials/nct04180371/"},{"id":"nct05163041","kind":"trial","name":"Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression","route":"/trials/nct05163041/"},{"id":"nct04561362","kind":"trial","name":"Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies","route":"/trials/nct04561362/"},{"id":"nct06225596","kind":"trial","name":"Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)","route":"/trials/nct06225596/"},{"id":"nct06840483","kind":"trial","name":"Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer","route":"/trials/nct06840483/"},{"id":"nct06933329","kind":"trial","name":"Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer","route":"/trials/nct06933329/"}],"company":[{"id":"novartis-venture-fund","kind":"company","name":"Novartis Venture Fund","route":"/companies/novartis-venture-fund/"},{"id":"sv-health-investors","kind":"company","name":"SV Health Investors","route":"/companies/sv-health-investors/"}],"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"roadmap":[{"id":"drug-discovery-roadmap","kind":"roadmap","name":"Drug discovery roadmap: screening in mice → maps of dependency → designing in silico","route":"/roadmaps/drug-discovery-roadmap/"}]}}